For people with end-stage kidney disease, a transplant isn’t just a treatment — it’s a lifeline.
Compared to long-term dialysis, kidney transplantation offers better outcomes, improved quality of life, and renewed hope. Yet for one group of patients, that hope often remains frustratingly out of reach.
These are highly sensitized patients, individuals whose immune systems are primed to reject most donor kidneys due to previous transplants, blood transfusions, or pregnancies. Their bodies are ready to fight off what could otherwise be a life-saving organ. As a result, they face longer wait times, fewer matches, and limited access to care.
But the challenge goes deeper than biology.
Many patients don’t even know they’re highly sensitized. The key test, cPRA (calculated panel reactive antibody), which identifies levels of sensitization, is often done too late in the care journey. Without early testing and clear communication, patients miss critical opportunities to be referred to specialized transplant centers that could offer them a chance.
The system is complex. The path is unclear. And the stakes are high.
To change this, we need coordinated action across the transplant community, including:
- Standardizing early cPRA testing
- Improving education and communication around results
- Strengthening referral pathways to specialized centers
- Ensuring the Kidney Allocation System continues to support equitable access
At Hansa Biopharma, we are committed to advancing transplant science and addressing the gaps that leave highly sensitized patients behind. These patients deserve more than hope, they deserve a system that works for them.
To learn more, visit hansabiopharma.com
